EASL Video Podcasts

In this EASL DeepDive webinar, the expert panel presents and explains the key studies behind the latest recommendations included in the EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma. Learning Objectives To identify patients at risk for eCCA, and review the current tools and strategies for its surveillance, diagnosis, staging, and classification To define the optimal candidates for resection and liver transplantation, and discuss challenges in the surgical management of eCCA To discuss the role of systemic therapy in the management of eCCA across all disease stages (including neoadjuvant, adjuvant, and palliative settings) Faculty Luca Maroni - Moderator Julie Heimbach - Speaker Anna Saborowski - Speaker Lars Aabakken - Speaker

In this EASL DeepDive, experts will discuss the latest advances in the EASL Clinical Practice Guidelines on the management of hepatitis B virus infection, published in the "Journal of Hepatology" in 2025. Learning objectives Understand the updated EASL recommendations for initiating and discontinuing antiviral therapy in chronic hepatitis B, including key differences with other HBV guidelines. Participants will be able to identify treatment indications and make informed decisions about when and how to stop antiviral therapy. Learn how to monitor patients with hepatitis B across different clinical scenarios, including those not on treatment, those receiving antiviral therapy, surveillance for hepatocellular carcinoma, risk of reactivation, and response to vaccination, in alignment with the new EASL guidelines. Explore future directions in the management of chronic hepatitis B as outlined in the EASL guidelines, including advances in nomenclature and antiviral therapies under development. Faculty Markus Cornberg - Moderator Maud Lemoine - Speaker Sabela Lens - Speaker Jerzy Jaroszewicz - Speaker

In this EASL DeepDive, experts will discuss the latest advances in the EASL Clinical Practice Guidelines on the management of autoimmune hepatitis, published in the "Journal of Hepatology" in 2025. Learning objectives Select induction and maintenance treatment strategies aimed at achieving complete biochemical response Recognise and manage disease flares, treatment intolerance, and suboptimal response in autoimmune hepatitis Understand tailored approaches to autoimmune hepatitis management in specific patient groups Faculty Mária Papp - Moderator Michael Heneghan - Speaker George Dalekos - Speaker Maria Carlota Londoño - Speaker

Hepatocellular carcinoma (HCC) is responsible for 75% of all primary liver cancers and is the third most prevalent cause of cancer death worldwide, with 900,000 new cases diagnosed each year. Many patients are diagnosed at an advanced stage, making curative treatment difficult. In this DeepDive Webinar, you’ll be guided through the latest advances in hepatocellular carcinoma management, from the rising impact of immunotherapy combinations to evolving approaches in intermediate-stage disease.  This EASL DeepDive webinar is supported by Bayer AG. Bayer AG has had no input into the content of this EASL DeepDive. Learning Objectives What are strategies to optimise surveillance and early diagnosis of hepatocellular carcinoma What are the optimal candidates for surgery (including liver transplantation) and locoregional therapies (alone or combined with immunotherapy) Optimal selection of systemic front-line regimens and treatment sequencing after first-line immunotherapy Faculty Manon Allaire - Moderator Fabio Piscaglia - Speaker Antonio D'Alessio - Speaker Anna Saborowski - Speaker

This EASL Studio episode brings key insights from the 2025 EASL–AASLD Consensus Conference on Primary Biliary Cholangitis (PBC). Experts explore the use of surrogate endpoints, the challenges in current trial design and regulation, the value of real-world evidence, and how quality-of-life assessment can support future pathways.   Moderator: David Jones Speakers: Marco Carbone, Bettina Hansen, and Ana Lleo   All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

How can we protect young adults from steatotic liver disease (SLD)? This episode explores the burden of MASLD, MetALD, and ALD in Europe, the synergistic effects of alcohol and metabolic risk factors, and why the younger population is especially vulnerable. Experts also examine the disparities in risk factors and the role of clinics and policymakers in prevention. Moderator: Shira Zelber Sagi Speakers: Carina Ferreira-Borges (WHO representative) and Zobair Younossi This EASL Studio is supported by Opella. EASL has received no input from Opella with regards to the content of this programme. All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

What were the key takeaways from this year’s AASLD The Liver Meeting? In this episode, experts unpack the most impactful studies, clinical insights, and emerging trends shaping the future of hepatology. From liver cancer breakthroughs to MASLD, ALD, and beyond. Moderator: Debbie Shawcross Speakers: Saul Karpen, Allison Kwong, Mazen Noureddin   All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

For World Antimicrobial Awareness Week 2025 (“Act Now: Protect Our Present, Secure Our Future”), this EASL Studio explores the balance between rifaximin’s benefits in hepatic encephalopathy and the global challenge of antimicrobial resistance. Moderator: Debbie Shawcross Speakers: Rajiv Jalan, Vishal Patel, Jonel Trebicka All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.   This EASL Studio is supported by Alfasigma and Norgine. EASL has received no input from Alfasigma or Norgine with regards to the content of this programme.

Ever wondered what happens to your manuscript after submission? In this episode, the JHEP Reports editorial team takes you behind the scenes: from first triage to reviewer selection, smart moves vs. red flags, and how final decisions are made. The discussion also explores the potential, limitations, and ethical pitfalls. Moderator: Mattias Mandorfer Speakers: Tobias Böttler, Virginia Hernández-Gea, and Josep Llovet All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

After years of limited progress, recent trials hint at a changing landscape for primary sclerosing cholangitis (PSC). In this episode, experts review emerging data and explore whether we’re approaching a new era of effective treatment. How should clinicians assess these therapies, and could they shift the current management of PSC? Moderator: Debbie Shawcross Speakers:  Cynthia Levy, Stephen Rossi, Michael Trauner All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

This episode questions whether assigning the label “ACLF” to a deteriorating patient truly alters clinical decisions, or if focusing on the specifics of organ failure and reversibility is more useful. Experts debate the real-world utility of prognostic scores, the clarity (or confusion) created by multiple definitions, and whether the ACLF concept drives urgency, facilitates transplant access, or improves outcomes. A thought-provoking look at where terminology meets bedside care. Moderator: Tom Marjot  Speakers: Paolo Angeli and Julia Wendon This EASL Studio is supported by GENFIT. EASL has received no input from GENFIT with regards to the content of this programme.  All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

This EASL Studio explores the discrepancy between the huge burden of patients hospitalised with, and dying from, alcohol-related liver disease (ALD) or MetALD, versus the same disease’s near non-existence from population data. The panel will discuss whether current classification systems (heavily favoring metabolic causes) misrepresent the true burden of ALD and MetALD, and what clinicians can do to better map the role of alcohol in liver patients. Moderator: Maja Thiele Speakers: Brian Lee, Mzamo Mbelle, Elisa Pose All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

What do we call it when someone with high-risk practices becomes viraemic again after treatment? In this episode, experts discuss the challenges of managing Hepatitis C in people who inject drugs (PWID) and other high-risk groups. Topics include SVR confirmation rates, DAA prescribing practices, acute vs. chronic infection, and real-world reinfection data. Are traditional labels still meaningful or do we need new frameworks for 2025? Moderator: Ahmed Elsharkawy Speakers: Ashley Brown, Tatyana Kushner and Sabela Lens This EASL Studio is supported by AbbVie. EASL has received no input from AbbVie with regards to the content of this programme. All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

In hepatology, effective care goes beyond diagnostics and treatment. This episode explores the crucial questions hepatologists should ask to truly understand their patients’ needs, values, and priorities. By focusing on communication and patient-centred care, our experts highlight how listening carefully can improve adherence, enhance quality of life, and ultimately lead to better outcomes. Moderator: Pierre-Emmanuel Rautou Speakers: Agnès Dumas, Maria Hjorth, José Willemse, Zobair Younossi All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

This first session in a two-part EASL DeepDive series on the 2024 EASL-EASD-EASO MASLD Clinical Practice Guidelines will provide a detailed examination of the recommendations concerning diagnosis, non-invasive assessment, and risk stratification, with a view to supporting evidence-based clinical practice. Learning objectives Have a good understanding of the concept/definition of MASLD within the framework of the new SLD nomenclature, including its contribution to disease progression in other diseases Get familiar with the role of non-invasive tests for risk stratification in MASLD, their pro- and cons, and how and in whom to use them for screening/case finding Get a detailed understanding of HCC risk and risk stratification in MASLD and the surveillance strategies to implement This programme is part of the EASL Guidelines Implementation Programme on MASLD supported by Boehringer Ingelheim and Novo Nordisk. Boehringer Ingelheim and Novo Nordisk have had no input in the selection and creation of this programme.

This episode addresses key challenges in vascular complications of liver disease, including the management of portal vein thrombosis (PVT) in patients with and without cirrhosis. Experts will explore controversies surrounding long-term anticoagulation therapy and discuss insights from the CIRROXABAN paper. Additionally, the episode will shed light on the management of splanchnic artery aneurysms, offering valuable guidance for clinical practice. Moderator:  Pierre-Emmanuel Rautou Faculty: Sarwa Darwish Murad, Juan-Carlos Garcia-Pagan, Valérie Vilgrain  Related episodes S4E11 – YI Choice: Gene therapy for liver disease — RNA interference and beyond S4E6 – Regenerating the liver graft with a machine? S3E11 – Regenerative Hepatology: From stem cells to tissue engineering S2E9 – YI Choice: Propelling liver cell biology into the third dimension All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

In this new edition of the EASL DeepDive, expert faculty guide participants through a focused and forward-looking discussion on key aspects of advanced MASLD, setting the stage for a deeper understanding of evolving clinical challenges and opportunities. This EASL DeepDive webinar is supported by Boehringer Ingelheim. Boehringer Ingelheim has had no input into the content of this EASL DeepDive. Learning objectives Understand the Pathophysiology: Describe the key pathophysiological mechanisms of MASLD and its progression to advanced liver disease and portal hypertension. Identify Unmet Clinical Needs: Recognise the current gaps in diagnosis, management, and treatment of advanced MASLD, highlighting the challenges of healthcare professionals in clinical practice. Evaluate Valuable Endpoints: Discuss the importance of selecting and utilising valuable clinical endpoints in managing MASLD to improve patient outcomes. Explore Emerging Therapies: Review the latest therapeutic strategies and potential interventions for advanced MASLD, focusing on how they address the unmet needs in patient care. All EASL DeepDive are available on EASL Campus.

This EASL Studio episode explores state-of-the-art practices in diagnosing steatotic liver disease and stratifying patients effectively for targeted treatment in 2025. Focusing on integrating cardiometabolic risk profiling and dynamic alcohol consumption assessment, the discussion will discuss contemporary methods, frequency, and practical implementation in clinical settings to enhance precision medicine approaches. Moderator: Aleksander Krag  Faculty: Meena Bansal, Mattias Ekstedt, Arun Sanyal  All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

Listen to this EASL Studio episode to explore how artificial intelligence (AI) is transforming healthcare. Discuss its potential to revolutionise medical practice, its limitations, and whether it poses a threat or an opportunity for the future of the medical profession. Moderator: Ahmed Elsharkawy   Faculty: Jakob Kather, Sabela Lens, Ashley Spann  Related episodes: EASL Studio at EASL Congress 2024 – Exploring new frontiers: The AI liver taskforce initiative S4E5 – AI for dummies S2E13 – Digital Pathology All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

With the release of the new HBV guidelines, treatment eligibility broadens. This EASL Studio explores how to communicate these changes, support shared decision-making, ensure adherence, and engage patients in ongoing care and clinical trials. Moderator: Ahmed Elsharkawy  Faculty: Markus Cornberg, Sital Shah, Thomas Tu, Su Wang This EASL Studio is supported by Aligos Therapeutics and Gilead Sciences Europe Ltd . EASL has received no input from Aligos Therapeutics or Gilead Sciences Europe Ltd with regards to the content of this programme. All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

Listen to this EASL Studio episode for insights on the new MASLD guidelines and their practical application. Hear from experts on navigating the nomenclature change, implementing guidelines in clinical workflows, and fostering behavioral change to improve patient outcomes across the care team. Moderator: Sven Francque  Faculty: Marta Cervera, Elena George, Shelley Keating This programme is part of the EASL Guidelines Implementation Programme on MASLD supported by Boehringer Ingelheim and Madrigal Pharmaceuticals. Boehringer Ingelheim or Madrigal Pharmaceuticals have had no input in the selection and creation of this programme. Related episode S5E5 – JHEP Live: The new nomenclature for SLD: A multidisciplinary evaluation and approach All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

Most liver diseases are diagnosed when it’s already too late. This episode explores the pros and cons of early screening, the gaps in current strategies, and how projects like LIVERAiM are aiming to change the game. Moderator: Ahmed Elsharkawy Faculty: Pere Ginès, Ian Rowe, Maja Thiele All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

What happens when hepatologists and interventional radiologists join forces? This episode discusses the power of collaboration – shared guidelines, joint training, and multidisciplinary care – to improve outcomes in complex liver disease. Moderator: Sven Francque Faculty: Irene Bargellini, Virginia Hernández-Gea, Max Seidensticker All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

Listen to this episode for a curated overview of landmark studies and breakthrough data presented at EASL Congress 2025, with expert insights on their clinical relevance and impact on the future of hepatology. Moderator: Thomas Berg  Faculty: Hannes Hagström, Verena Keitel, Raj Mookerjee All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

This EASL Studio episode cuts through the noise to explore alcohol’s true impact on health and society, spotlighting patient stories, public misconceptions, and bold policy solutions from across Europe. Moderator: David Barret (Internal Communications and Multimedia Manager, WHO Regional Office for Europe) Faculty: Carina Ferreira-Borges (Regional Advisor for Alcohol, Illicit drugs and Prison health, WHO Regional Office for Europe), Aleksander Krag (EASL Secretary General), Hazel Martin (BBC Journalist and Liver Patient), Margarida Santos (General Practitioner Portugal), Riina Sikkut (Member of Estonian Parliament, former Minister of Health of Estonia) All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

In this fifth edition of the EASL DeepDive, join Christophe Bureau, Virginia Hernandez-Gea, Marika Rudler, and Manhal Izzy to gain expert insight into the selection, management, and outcomes of patients undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures. This EASL DeepDive webinar is supported by W. L. Gore & Associates. W. L. Gore & Associates has had no input into the content of this EASL DeepDive. Learning objectives Understand the criteria for selecting appropriate patients for Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures Learn to differentiate between high-risk and low-risk patients based on clinical indicators and patient history Explore the impact of cardiopulmonary conditions on the outcomes of TIPS procedures, and how/when to monitor for new-onset heart failure post TIPS Learn from Marika Rudler about the strategies for preventing and managing post-TIPS hepatic encephalopathy (HE) Discuss the latest research and treatments available for managing EH in TIPS patients

This EASL Studio episode discusses cutting-edge approaches for managing bleeding varices. Explore the evolution of endoscopic therapies, the role of interventional radiology, and decision-making for high-risk gastric varices. Gain insights into EUS-guided portal pressure assessment and its impact on tailoring treatment strategies. Moderator: Debbie Shawcross Faculty: Wim Laleman, David Patch Related episode S6E14: Endohepatology: The endoscopic liver gold rush All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

This episode celebrates 40 years of the Journal of Hepatology, EASL’s flagship journal. Tune in to discover how far we’ve come—and what’s next for the journal. Moderator: Thomas Berg  Faculty: Paolo Angeli, Annalisa Berzigotti, Rajiv Jalan, Vlad Ratziu, Frank Tacke and Jessica Zucman-Rossi All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

Rare liver tumors like combined HCC/CCA, fibrolamellar HCC, and haemangioendothelioma pose significant diagnostic and therapeutic challenges. In this episode, we explore the latest insights, controversies, and clinical approaches outlined in the new EASL position paper. Join us to uncover how these advancements can address key hurdles in managing these rare malignancies. Read the position paper: Rare primary liver cancers: An EASL position paper Moderator: Thomas Berg Faculty: Ruben de Kleine and Henning Wege Related episodes S6E4: World Cholangiocarcinoma Day: Highlighting guidelines and exploring the horizon beyond S5E13: Basics in decision-making for liver cancer treatment S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

This episode of EASL Studio explores insights from the European Alcohol Health Alliance Symposium, hosted by the WHO Regional Office for Europe in collaboration with EASL. Topics include managing alcohol marketing strategies, addressing gaps in cancer-related labelling, and understanding the influence of social norms on adolescent alcohol consumption. Learn from successful alcohol policy implementations and discover how the WHO Playbook can empower advocates to protect children and reshape public health strategies for alcohol-related harm. Moderator: Shira Zelber-Sagi Faculty: Frank Murray, Catherine Paradis (WHO Europe) and Debbie Shawcross Related episodes S7E5 Why does WHO engagement with Steatotic Liver Disease matter? S6E7 The impact of policy measure in preventing liver diseases: The Hepahealth II study EASL Studio live from EASL Congress 2023: The battle to reduce alcohol harms… EASL’s new policy S3E5 JHEP Live: Stigma and alcohol All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects men and women differently, yet sex-based differences remain poorly explored. In the week celebrating International Women’s Day, this EASL Studio episode debates the molecular, hormonal, and genetic mechanisms driving these disparities. Moderator: Saskia van Mil Faculty: Sara Della Torre and Münevver Demir Related episode S4E9 YI Choice: Gender equality in academics — reducing the gap All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

Tune into this EASL Studio episode to learn about the role of PET imaging in Wilson’s disease. Discover how PET advances understanding, supports treatment decisions, and enhances patient care in managing this rare liver disorder. Moderator: Debbie Shawcross Faculty: Aftab Ala, Zoe Mariño and Thomas Sandahl This EASL Studio is supported by Orphalan and Univar Solutions. EASL has received no input from Orphalan or Univar Solutions with regards to the content of this programme. Related episodes S4E15: Diagnostic and therapeutic challenges in Wilson’s disease S4E7: Genetics in adult liver disease – missed opportunities? All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

Join this EASL Studio episode for a clinical perspective on advancing HCC care. Explore the realities of adjuvant therapies, emerging molecular targets, and strategies for curative conversion. Gain insights into practical innovations shaping the future and translating research into improved patient outcomes. Moderator: Thomas Berg Faculty: Tim Greten and Anna Saborowski This EASL Studio is supported by Bayer. EASL has received no input from Bayer with regards to the content of this programme. Related episodes EASL Studio S5E13: Basics in decision-making for liver cancer treatment EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023 EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023 EASL Studio S6E9: Therapy hierarchy in HCC: A new kid on the block All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

Watch this EASL Studio to start navigating your research journey with essential tips on generating ideas, refining hypotheses, and crafting standout abstracts for EASL Congress. Discover how to choose the right journal, prepare a submission-ready manuscript, and boost your career visibility in hepatology. Moderator: Thomas Marjot Faculty: Marta Afonso, Emma Andersson and Paolo Angeli Related episodes S4E20 – COST Actions: Opportunities for pan-European collaborations in liver diseases S4E14 – EASL-EF CLIF and EU Grants: Exploring novel mechanism and treatment of chronic liver failure S4E2 YI Choice – How to build consortia and registries All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

Discover the latest updates from the updated EASL Clinical Practice Guidelines on Hepatocellular Carcinoma (HCC). This episode explores key advancements, their impact on clinical practice, and how they will shape the future of HCC diagnosis, treatment, and management. Join our faculty as they break down the changes and provide practical insights for healthcare professionals. Moderator: Thomas Berg Faculty: Peter Galle, Josep Llovet and Lorenza Rimassa Related episodes EASL Studio S6E4: World Cholangiocarcinoma Day: Highlighting Guidelines and Exploring the Horizon Beyond EASL Studio S6E9: Therapy Hierarchy in HCC: A New Kid on the Block EASL Studio S5E13: Basics in Decision-Making for Liver Cancer Treatment EASL Studio Live from EASL Congress 2024: Advances in Systemic Treatments in Liver Cancer All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

Join us for the season premiere of EASL Studio Season 8 as we unpack key insights from the Steatotic Liver Disease (SLD) Summit. Explore the evolving consensus on patient trajectories, advancements in ALD and MetALD treatment pathways, and the latest endpoint discussions. The episode also highlights a holistic approach to diagnosing and managing comorbidities and revisits the standard of care in light of breakthroughs in MASH treatments. Moderator: Aleksander Krag Faculty: Cyrielle Caussy, Sven Francque and Brian Lee This EASL Studio is supported by Madrigal. EASL has received no input from Madrigal with regards to the content of this programme. Related episodes S7E3 – The changing face of Steatotic Liver Disease: Navigating new opportunities and emerging challenges EASL Studio at the Congress 2024: SLD nomenclature: Need for refinement? EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscape EASL Studio from EASL Congress 2023 – Steatotic liver disease global consensus to change nomenclature All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

In this EASL DeepDive held on 03 July 2024, Palak Trivedi, Emma Culver, Andreas Kremer and Jessica Dyson explain the risk assessment in people with PBC as well as the mechanistic and treatment of fatigue and pruritus. Learning objectives Discover the latest mechanistic insights relating to the occurrence of PBC symptoms Learn more about the holistic management of PBC symptoms, with a particular emphasis on fatigue and pruritus Learn more about the current treatment options, their efficacy and limitations Get a detailed understanding of the drugs in the pipeline for the near future This EASL DeepDive webinar is supported by GSK and IPSEN. GSK and IPSEN have had no input into the content of this EASL DeepDive.

In this EASL DeepDive held on 30 October 2024, Henning Grønbæk, Cyrielle Caussy, Mazen Noureddin and Frank Tacke provide an understanding of the role of glucagon and glucagon-receptors in physiology and in MASH patients. Additionally, they review key clinical trials and evaluate the integration of GLP-1 receptor agonists into current EASL-EASD-EASO clinical guidelines for practical patient management. Learning objectives: Understand the role of glucagon and glucagon-receptor in normal physiology and disease. Understand the rationale of a combined dual GLP-1/GCG RA and its potential benefit compared to a GLP-1RA alone and thus gain insights into the mechanisms through which GLP-1 receptor agonists and GLP-1/GCG might affect liver pathology and metabolic regulation. Discuss and review key clinical trials and ongoing development programs. Evaluate how GLP-1RA can be integrated into current EASL-EASD-EASO CPGs, with a focus on practical applications and patient management strategies, giving potential guidance for future applications. This EASL DeepDive webinar is supported by Boehringer Ingelheim. Boehringer Ingelheim has had no input into the content of this EASL DeepDive.

In this EASL DeepDive held on 06 November 2024, Alice Turner, Pavel Strnad, and Nicola Brunetti discuss and explore the changing insights in the management of Alpha-1 Antitrypsin Deficiency. Learning objectives: Learn more about the role of heterozygosity of alpha-1 as a risk factor for chronic liver disease, especially in the context of other causes such as MASLD or alcohol Get a better understanding of the extrahepatic manifestations and the need for a multi-disciplinary approach Learn more about screening: who to screen and how Discover the general unmet needs related to AAT, with an emphasis on awareness and timely diagnosis This EASL DeepDive webinar is supported by Takeda Pharmaceuticals. Takeda Pharmaceuticals has had no input into the content of this EASL DeepDive.

In this EASL DeepDive held on 25 February 2025,  Ana Lleo, Adriaan van der Meer, Gideon Hirschfield, and Bettina Hansen explore the future of primary biliary cholangitis (PBC) treatment. Discover the emerging therapies, current challenges and personalised approaches that are shaping the management of PBC. Learning objectives Learn more about the molecular mechanisms underlying the disease and the potential targets for drug therapy Get a good understanding of the efficacy of the current drugs and the potential added value of the upcoming second line treatments for PBC and where to position these new treatments in the treatment landscape Learn more about the evolving concepts regarding the endpoints in clinical trials for PBC Get insights in the risk assessment of people living with PBC and criteria for second line therapy  This EASL DeepDive webinar is supported by Gilead. Gilead has had no input into the content of this EASL DeepDive.